Mitochondrial Replacement for Infertility Faces an Evidence Test

On November 2, 2026, STAT published an eight-month investigation into mitochondrial replacement therapy (MRT) marketed internationally to women with age-related fertility concerns. Its reporters interviewed 45 people and reviewed business records, contracts and other materials.

Fertility marketing has moved beyond the evidence

The evidence described by STAT does not establish MRT as a reliable treatment for age-related infertility. A technology developed to reduce transmission of serious inherited mitochondrial disease is being promoted for a different purpose: improving fertility by supplying younger mitochondria to older eggs. For healthy-aging research, the central issue is whether changing a component of an aging cell addresses the cause of its declining function. The investigation shows why a biological rationale needs to be tested against clinical outcomes rather than treated as proof of reproductive rejuvenation.

Evidence setting: Procedures performed in humans and laboratory research on human embryos, not animal models. STAT's investigation was journalistic reporting, not a new clinical trial or a study measuring human healthspan or longevity.

Disease prevention and fertility treatment require different biological arguments

In the form of MRT described by STAT, nuclear genetic material from the intended parents is transferred into a donor egg whose nucleus has been removed. The resulting embryo has nuclear DNA from the intended parents and mitochondrial DNA from the donor. This arrangement provides the basis for reducing the risk of passing on a serious inherited mitochondrial disorder.

The proposed fertility application makes a separate argument. Instead of seeking to prevent transmission of a particular mitochondrial disease, it aims to improve the performance of an older egg through younger mitochondria. These purposes involve the same broad technology but ask different clinical questions. Evidence supporting disease prevention therefore does not automatically validate a fertility claim.

The distinction matters when interpreting language about cellular renewal. For evaluating longevity claims, the useful boundary is between a mitochondrial rationale and demonstrated human benefit. A proposed intervention needs evidence connecting the biological change it produces with the outcome being advertised.

For MRT marketed as a fertility intervention, that outcome is not simply successful transfer of genetic material. It is a live birth in the patient population being offered treatment, alongside an adequate assessment of safety. The research question is whether the intervention improves that outcome compared with an appropriate alternative, not whether mitochondrial biology is important enough to attract scientific interest.

The evidence gaps change how results should be read

STAT reported that hundreds of women had traveled abroad for MRT over the past decade. One intermediary was International Fertility Group of North America (IFG), based outside Chicago. IFG described itself as a facilitator rather than a clinic and said it did not perform procedures.

According to STAT, IFG temporarily paused acceptance of new MRT patients after reporters began asking questions. The company later said it had suspended MRT-related promotion pending a comprehensive review. It also told STAT that patients were not promised pregnancy or live birth and that it did not describe innovative treatments as guaranteed or risk-free.

The investigation identified several distinct weaknesses that affect how the available evidence should be interpreted:

• The published study did not represent the older population being targeted. STAT described a peer-reviewed study of 25 patients under 40 who received spindle transfer at a clinic in Greece. It reported a 31.6% live-birth rate per transfer overall. Among its 12 patients aged 39, the reported rate was below 10%. The small sample and age distribution mean that the overall result should be read as a finding in those participants, not as an estimate for women over 40.
• Commercial pregnancy claims lacked the detail needed for interpretation. IFG's website had cited a pregnancy rate above 50%, which the company did not substantiate for STAT or break down by age. A webinar slide put its average patient age at 39.2 in 2022 and 45.6 in 2025. These figures describe different things: a claimed pregnancy rate and a change in the program's patient population. To assess a claim, the relevant information includes live births and clearly defined denominators, with outcomes separated by age and treatment cycles.
• Birth counts did not establish that MRT caused the outcome. IFG said its program had resulted in 34 births as of February 2025; STAT could not verify a newer total. The outlet also described a successful pregnancy involving an additional egg-maturation procedure, leaving the embryologist unable to say whether MRT contributed. A birth is an important outcome but does not isolate which part of a treatment process made the difference. The appropriate research question is comparative benefit rather than the existence of a successful case.
• Another publication raised concerns about data quality and commercial involvement. A paper coauthored by people associated with commercial MRT services claimed a 48.3% average live-birth rate among 27 older patients and a 33% rate among women over 42. Experts reviewing it for STAT questioned its publication process and data quality. The paper also did not show that offspring had high levels of donor mitochondria. Those concerns make independent scrutiny essential before using the figures to support claims about either effectiveness or the proposed mitochondrial mechanism.
• The unpublished embryo experiments had scientific and ethical shortcomings. STAT reviewed data from Ukrainian embryologist Pavlo Mazur in which only one of 19 patients obtained an embryo with the correct chromosome number after pronuclear transfer. The manuscript was rejected in part because the experiments lacked patient consent and ethics-board permission. These findings should not be treated as equivalent to a controlled clinical trial or directly compared with commercial success rates. They illustrate why laboratory findings and clinical efficacy require separate assessment.
• The proposed cause of age-related infertility remained uncertain. Reproductive endocrinologist Mary Herbert told STAT that direct evidence linking mitochondrial dysfunction to age-related fertility decline was “very, very sparse.” Experts interviewed for the investigation also pointed to chromosomal errors in older eggs. Embryologist Birol Aydin did not rule out benefits for some patients but acknowledged that fertility problems have multiple causes and MRT may not address them. The question for evaluating the mechanism is whether there is evidence that the intervention targets the problem in the population being studied.
• Long-term safety requires more than a pregnancy or birth report. Medical ethicist Jeffrey Kahn told STAT that assessing safety may require follow-up into adulthood and potentially across generations. He also questioned whether paying patients were effectively serving as experimental subjects. For an intervention involving future children, independent oversight and meaningful informed consent are central to evaluating the research. Published outcome reports therefore need to explain how follow-up is organized rather than ending the account at pregnancy or delivery.
• Fragmented care and different legal systems complicate accountability. STAT reported that MRT is not legal in the United States and that a 2015 congressional spending restriction has prevented the FDA from considering applications to test it in human embryos. UK use is permitted for preventing mitochondrial disease with case-by-case approval. International offers should therefore be assessed by their actual indication and oversight arrangements, not assumed to carry equivalent safeguards. Individual decisions warrant discussion with a qualified fertility specialist who can distinguish the provider's role from that of an intermediary.

Transparency connects these weaknesses. Alongside its investigation, STAT published a request to hear from people pursuing MRT for infertility. Its reporting described a system in which coordination and treatment can involve multiple companies and jurisdictions, making consistent outcomes difficult to obtain.

For research-minded readers, the practical task is to identify exactly what each claim measures. A reported pregnancy rate answers a different question from a live-birth rate in a defined age group. A provider's explanation of why a procedure might work also needs to remain separate from evidence that it improves outcomes.

Age-specific controlled studies are the next test

The next research priority is independently overseen controlled studies with age-specific live-birth outcomes and long-term follow-up to test whether MRT benefits patients with age-related infertility.

How AgeAmaze helps

Live birth within a defined age group is a more specific outcome than a broad reproductive-rejuvenation claim, and AgeAmaze makes the science behind such distinctions easier to understand. Overstated claims about emerging interventions can obscure that difference; its reporting gives research-minded readers context about biological mechanisms and evidence quality without presenting early findings as established benefits.

Read the research

Sources

1. Women travel thousands of miles for a reproductive moonshot. Scientists say they've been misled
2. Are you pursuing MRT as a treatment for infertility? Tell us ...